

P-tau217 and other blood biomarkers of dementia: variation with time of day

Ciro della Monica^{1,2}, Victoria Revell^{1,2}, Giuseppe Atzori^{1,2}, Rhiannon Laban³, Simon S. Skene⁴,
Amanda Heslegrave^{3,5}, Hana Hassanin^{2,6,7}, Ramin Nilforooshan^{2,8}, Henrik Zetterberg^{3,5,9,10},
^{11,12}, Derk-Jan Dijk^{1,2}

¹Surrey Sleep Research Centre, University of Surrey, Guildford, Surrey, GU2 7XP, UK.

²UK Dementia Research Institute Care Research & Technology Centre, Imperial College London and University of Surrey.

³UK Dementia Research Institute at UCL, London, UK.

⁴Surrey Clinical Trials Unit, University of Surrey, Guildford, Surrey, GU2 7XP, UK.

⁵Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square; London, UK.

⁶Surrey Clinical Research Facility, University of Surrey, Guildford, Surrey, GU2 7XP, UK.

⁷NIHR Royal Surrey CRF, Guildford, UK.

⁸Surrey and Borders Partnership NHS Foundation Trust Surrey, Chertsey, Surrey, KT16 0AE.

⁹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

¹⁰Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

¹¹Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.

¹²Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding Author: Derk-Jan Dijk, Surrey Sleep Research Centre, University of Surrey, Guildford, Surrey, GU2 7XP, UK. Telephone: +44 (0)1483 689341. Email:

d.j.dijk@surrey.ac.uk

Abstract

Plasma biomarkers of dementia, including phosphorylated tau (p-tau217), offer promise as tools for diagnosis, stratification for clinical trials, monitoring disease progression, and assessing the success of interventions in those living with Alzheimer's disease. However, currently, it is unknown whether these dementia biomarker levels vary with time of day, which could have implications for their clinical value. In two protocols, we studied 38 participants (70.8 ± 7.6 years; mean \pm SD) in a 27-hour laboratory protocol with either two samples taken 12 hours apart or 3-hourly blood sampling for 24 hours in the presence of a sleep-wake cycle. The study population comprised people living with mild Alzheimer's disease (PLWA, $n = 8$), partners/caregivers of PLWA ($n = 6$) and cognitively intact older adults ($n = 24$). Single molecule array technology was used to measure phosphorylated tau (p-tau217) (ALZpath), amyloid-beta 40 ($A\beta_{40}$), amyloid-beta 42 ($A\beta_{42}$), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) (Neuro 4-Plex E). Analysis with a linear mixed model (SAS, PROC MIXED) revealed a significant effect of time of day for p-tau217, $A\beta_{40}$, $A\beta_{42}$, and NfL, and a significant effect of participant group for p-tau217. For p-tau217, lowest levels were observed in the morning upon waking and highest values in the afternoon/early evening. The magnitude of the diurnal variation for p-tau217 was similar to the reported increase in p-tau217 over one year in amyloid- β -positive mild cognitively impaired people. Currently, the factors driving this diurnal variation are unknown and could be related to sleep, circadian mechanisms, activity, posture, or meals. Overall, this work

implies that time of day of sample collection may be relevant in the implementation and interpretation of plasma biomarkers in dementia research and care.

Introduction

Alzheimer's disease (AD) is the most prevalent form of dementia, accounting for up to 80% of all cases, and hallmarks of the disease include amyloid plaques and hyperphosphorylated tau tangles in the brain [1, 2]. There is no standard approach to diagnose AD and disease presence cannot be determined by a single test but is rather a multi-faceted and multi-disciplinary approach involving taking medical history, cognitive tests, amyloid-PET scans, and sometimes cerebrospinal fluid (CSF) samples for measurement of beta-amyloid or tau [2]. However, imaging and CSF tests may not always be possible due to cost, availability of equipment, and the invasiveness of procedures which may not be well tolerated [3]. Nevertheless, the ability to confirm amyloid-beta pathology in the brain will become increasingly important with the advance of disease-modifying therapies (DMTs) targeting amyloid beta e.g., aducanumab [4], lecanemab [5] and donanemab [6], as one of the requirements for prescribing these DMTs is confirmation of brain amyloid burden [7]. Thus, there is a need for acceptable, scalable, and accurate diagnostic approaches to determine disease presence, severity, and response to any treatment.

Plasma biomarkers offer an opportunity as a cost- and time- effective tool that is minimally invasive for screening and diagnosis, stratification, monitoring disease progression, and assessing treatment response. Biomarkers that have been proposed include amyloid-beta (A β 40, A β 42, and their ratio), phosphorylated tau (p-tau181, p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) (reviewed in [1]). The sensitivity and specificity of these biomarkers is an area of active research. In particular,

p-tau217 has been demonstrated to be a valuable biomarker for predicting cognitive decline and monitoring treatment efficacy in response to DMT [8, 9].

Although plasma biomarkers, and particularly p-tau217, show great promise as clinical tools very little is known about non-disease related factors that may influence the concentrations of these biomarkers in blood. Biomarker levels may vary between individuals due to demographic or comorbid factors (inter-individual variation), but they may also vary within an individual due to behaviour or biological processes (intra-individual variation). Factors of interest include demographic variables such as age and sex, but also behavioural factors such as activity, posture, and eating and drinking. One factor of particular interest is time-of-day since many physiological variables in blood display 24-h rhythmicity. However, to date, the impact of time-of-day has not been taken into consideration for the implementation of plasma biomarkers for dementia. The importance of time of day for diagnostic samples has already been demonstrated in other clinical conditions. For example, for people living with severe asthma, sputum samples from morning clinic have significantly higher levels of eosinophils than samples from afternoon clinics [10] which may impact on clinical decision making.

Here, in a controlled laboratory setting, we explored whether plasma levels of biomarkers of dementia-related brain changes over the course of a 24-hour day (that includes a sleep/wake cycle and meals) in a heterogenous group of participants consisting of people living with mild Alzheimer's disease (PLWA), their caregivers, and cognitively intact older adults.

Materials and methods

Participants

Demographics

Data were collected from participants who were enrolled in one of two studies: 1) in cognitively intact older adults, 2) in PLWA, their study partner, and cognitively intact older adults. Eligibility was assessed using pre-defined inclusion/exclusion criteria for each of the three study groups. PLWA had to be 50 – 85 years old with a confirmed diagnosis of prodromal or mild AD, have an SMMSE (Standardised Mini Mental State Examination [11]) score ≥ 23 , be living in the community and be on a stable dose of any medication for dementia for at least three months. The diagnosis of prodromal or mild AD was based on clinical history, cognitive tests, and CT/MRI imaging. PLWA could participate in the study by themselves, or they could have a ‘study partner’ who must have known them for at least six months and could be their carer or a family member or friend. Study partners were ≥ 18 years and had to have an SMMSE score ≥ 27 . Cognitively intact older adults had to be aged 50 – 85 years, have an SMMSE score ≥ 27 (Study 2), and any comorbidities and concomitant medications must have been stable for the past three months. Cognitively intact adults were recruited via the Surrey Clinical Research Facility database. Potentially eligible PLWA and their study partners were identified via Surrey and Borders Partnership NHS Foundation Trust (SABP) memory services and were approached by one of the SABP team initially by telephone to discuss the study before being provided with the participant information sheet.

Ethics

Study One (cognitively intact older adults) received a favourable opinion from the University of Surrey Ethics Committee, and Study Two (PLWA, caregivers of PLWA, and cognitively

intact older adults) received a favourable opinion from an NHS ethics committee (22/LO/0694). Study Two is ongoing and is registered as a clinical study on the ISRCTN (International Standard Randomised Controlled Trial Number) registry (ISRCTN10509121). The protocols were conducted in accordance with the Declaration of Helsinki and guided by the principles of Good Clinical Practice. All personal data was handled in accordance with the general data protection regulations (GDPR) and the UK Data Protection Act 2018. Written informed consent was obtained from participants prior to any study procedures being performed. Participants were compensated for their time and inconvenience.

Procedures & Measures

The full study protocols have been reported in detail elsewhere [12, 13]. Briefly, following a screening visit to assess eligibility, participants were monitored for up to 14 days at-home using a variety of technologies to assess their sleep-wake patterns, environment, and cognitive function. They then attended the UK-DRI Clinical Research Facility at the University of Surrey for a 27-hour residential session which included a full clinical polysomnography (PSG) recording during an extended 10-hour period in bed. PSG was recorded using the Somnomedics SomnoHD system with Domino software (v 3.0.0.6; sampled at 256 Hz; SOMNOmedics GmbH, Germany) with an American Academy of Sleep Medicine (AASM) standard adult montage.

During the residential session, participants remained in environmentally controlled bedroom environments with en-suite facilities. For PLWA and their study partners, the aim was to recreate their sleeping situation at home so they could either share a room in a double occupancy suite or could be in adjacent rooms with an interconnecting door. During the afternoon/evening/morning hours participants were free to pursue their own activities

around scheduled procedures including sample collection, meals, questionnaire completion, and having PSG equipment attached. In Study One, dinner was scheduled ~5 hours before habitual bedtime (at approximately 18:30 h) and breakfast ~2 hours after habitual waketime (at approximately 09:30 h). In Study Two, lunch was ~9.5 hours and dinner was ~4 hours before habitual bedtime; breakfast was ~1.5 hours after habitual waketime.

In Study One, all participants had two blood samples drawn 12 hours apart via venepuncture at $19:46 \pm 00:33$ h and $07:53 \pm 00:35$ h (mean \pm SD). The evening sample was 2.88 ± 0.80 hours before Lights Off, and the morning sample was 0.68 ± 0.92 hours after Lights On. In Study Two, participants had an indwelling cannula sited and blood samples were drawn at three-hourly intervals relative to their habitual bedtime. Sampling began nine hours before habitual bedtime and continued until 15 hours after habitual bedtime.

Blood samples were collected into potassium EDTA tubes, were centrifuged immediately upon collection, and the plasma fraction was separated and stored at -80°C . Samples were shipped to the UK DRI Biomarker Factory, UCL, London where they were analysed using Simoa HD-X technology. The following biomarkers were measured in both studies using the Neuro 4-PlexE assay kit (Quanterix, Billerica MA): amyloid-beta 40 (Ab40), amyloid-beta 42 (Ab42), glial fibrillary acidic protein (GFAP), neurofilament light (NfL). Tau phosphorylated at threonine 217 (p-tau217) was measured using the ALZpath Simoa assay and measured in Study two only (ALZpath, Carlsbad, CA). Samples were measured in singlicate, and four internal controls made of pooled plasma were used to monitor any intra-and inter-plate variation. All coefficients of variation for internal controls were below 10%.

Data analysis

The data were analysed for all participants combined and separately for each group (PLWA, Study Partner, Cognitively intact) and, for each of the five biomarkers as well as the A β 42/A β 40 ratio. For each biomarker, the mean values at each timepoint were computed and also intraclass correlations (ICCs) were calculated using R Statistical Software (v4.2.2; R Core Team 2022). A PROC MIXED linear model was run in SAS (v9.4, SAS Institute Inc), and LS (least squares) means generated, using the Study Two datasets (nine timepoints) or the combined Study One and Two datasets (two timepoints) to assess the impact of time-of-day, group, and any interaction. For the two timepoint comparison, the timepoints used for the Study Two datasets were three hours before and nine hours after habitual bedtime; p-tau217 was only from Study Two but all other biomarkers were combined Study One and Two datasets. An extended PROC MIXED linear model was run for both the nine and two timepoint datasets where in addition to time and group, the following five factors were included as covariates: age, sex, BMI, PSQI, and AHI.

Results

Here we report data from 38 participants. The cognitively intact adults included 17 from study one (72.0 \pm 4.5 years; 11M: 6F; 28.9 \pm 1.3 SMMSE; 26.4 \pm 4.7 kg/m² BMI) and seven from study two (67.0 \pm 6.2 years; 4M: 3F; 28.9 \pm 1.1 SMMSE; 26.4 \pm 3.8 kg/m² BMI). We enrolled eight PLWA (74.8 \pm 4.4 years; 4M: 4F; 27.0 \pm 1.8 SMMSE; 29.7 \pm 7.6 kg/m² BMI), and six partners of PLWA (66.7 \pm 14.8 years; 3M: 3F; 28.8 \pm 1.0 SMMSE; 28.9 \pm 4.2 kg/m² BMI). Comorbidities included hypertension, Type-2 diabetes, arthritis, hyperthyroidism, and asthma [12, 13]

For both studies combined, 90% of scheduled samples were obtained. The plasma levels for each biomarker at each timepoint (mean \pm SD) are given in Table 1 for all participants combined as well as separately for each group for the nine timepoint comparison (Study Two). The ICCs for all participants combined ranged between 0.84 and 0.97 for the different biomarkers and the values were similar across groups. Table 2 provides a similar comparison for the two timepoint comparison, and here the ICCs range from 0.76 to 0.93 for all participants combined. These ICC values imply that the between-participant variation is greater than the within-participant variation and that this is similar across groups.

Table 1. Plasma biomarker levels (pg/mL, mean \pm SD) across a 24-hour period.

Variable	Group	Statistics	Time point (approximate clock time)									ICC (95% CI)
			1 (14:00)	2 (17:00)	3 (20:00)	4 (23:00)	5 (02:00)	6 (05:00)	7 (08:00)	8 (11:00)	9 (14:00)	
P-tau217	Total sample	Mean	0.789	0.686	0.767	0.671	0.674	0.670	0.653	0.612	0.654	0.97 (0.96,0.99)
		SD	0.593	0.501	0.676	0.481	0.498	0.514	0.519	0.472	0.496	
		N	20	20	21	17	17	17	20	17	17	
	Cognitively Intact	Mean	0.361	0.378	0.348	0.346	0.341	0.337	0.332	0.327	0.385	0.89 (0.74,0.98)
		SD	0.118	0.091	0.129	0.094	0.101	0.128	0.114	0.121	0.205	
		N	7	7	7	7	7	7	7	7	6	
	PLWA	Mean	1.272	1.127	1.323	1.248	1.297	1.294	1.144	1.129	1.121	0.95 (0.89,0.99)
		SD	0.660	0.599	0.810	0.440	0.420	0.470	0.591	0.564	0.565	
		N	8	7	8	5	5	5	7	5	6	
Study partner	Mean	0.615	0.530	0.515	0.550	0.518	0.511	0.455	0.494	0.415	0.94 (0.85,0.99)	
	SD	0.245	0.280	0.269	0.317	0.301	0.312	0.243	0.237	0.164		
	N	5	6	6	5	5	5	6	5	5		
A β 40	Total sample	Mean	122.420	119.280	123.916	125.762	129.257	123.698	118.405	111.887	124.890	0.86 (0.77,0.93)
		SD	26.665	24.698	30.104	26.949	27.169	23.497	23.771	26.566	22.899	
		N	20	20	21	17	17	17	20	17	17	
	Cognitively Intact	Mean	117.884	118.666	121.981	128.279	128.248	124.966	114.608	106.928	124.004	0.87 (0.71,0.97)
		SD	32.883	30.941	33.746	27.547	32.163	26.646	26.635	25.072	26.415	
		N	7	7	7	7	7	7	7	7	6	
	PLWA	Mean	131.905	124.608	134.932	127.641	138.823	134.975	129.656	120.552	125.563	0.84 (0.67,0.96)
		SD										
		N										

		<i>SD</i>	22.686	19.975	31.770	24.622	24.064	18.901	20.061	29.313	24.201	
		<i>N</i>	8	7	8	5	5	5	7	5	6	
	Study partner	<i>Mean</i>	113.59	113.781	111.484	120.360	121.104	110.645	109.710	110.166	125.144	0.88 (0.72,0.98)
			7									
		<i>SD</i>	23.273	24.776	21.460	33.294	24.953	20.281	22.910	29.671	22.164	
		<i>N</i>	5	6	6	5	5	5	6	5	5	
Aβ42	Total sample	<i>Mean</i>	7.941	8.015	8.110	8.370	8.575	8.294	7.884	7.342	8.134	0.84 (0.74,0.92)
		<i>SD</i>	1.645	1.595	1.884	1.774	1.714	1.559	1.699	1.465	1.547	
		<i>N</i>	20	20	21	17	17	17	20	17	17	
	Cognitively Intact	<i>Mean</i>	8.303	8.477	8.591	9.192	9.299	9.111	8.276	7.769	8.769	0.83 (0.65,0.96)
		<i>SD</i>	2.036	2.060	2.448	1.699	1.994	1.886	2.038	1.514	1.607	
		<i>N</i>	7	7	7	7	7	7	7	7	6	
	PLWA	<i>Mean</i>	8.105	8.006	8.475	7.646	7.934	7.847	8.162	6.891	7.801	0.86 (0.7,0.96)
		<i>SD</i>	1.517	1.310	1.643	1.666	1.382	0.935	1.527	1.382	1.516	
		<i>N</i>	8	7	8	5	5	5	7	5	6	
	Study partner	<i>Mean</i>	7.171	7.488	7.062	7.943	8.202	7.596	7.104	7.194	7.773	0.82 (0.61,0.97)
		<i>SD</i>	1.257	1.372	1.171	1.850	1.507	1.222	1.458	1.623	1.594	
		<i>N</i>	5	6	6	5	5	5	6	5	5	
Aβ42/ Aβ40	Total sample	<i>Mean</i>	0.066	0.068	0.066	0.067	0.067	0.068	0.067	0.067	0.066	0.92 (0.87,0.96)
		<i>SD</i>	0.011	0.011	0.010	0.009	0.009	0.009	0.009	0.011	0.010	
		<i>N</i>	20	20	21	17	17	17	20	17	17	
	Cognitively Intact	<i>Mean</i>	0.071	0.072	0.071	0.072	0.073	0.073	0.072	0.074	0.071	0.9 (0.76,0.98)
		<i>SD</i>	0.011	0.011	0.008	0.010	0.007	0.009	0.008	0.011	0.006	
		<i>N</i>	7	7	7	7	7	7	7	7	6	
	PLWA	<i>Mean</i>	0.062	0.065	0.064	0.060	0.057	0.059	0.063	0.058	0.063	0.95 (0.88,0.99)

		<i>SD</i>	0.012	0.014	0.013	0.008	0.005	0.008	0.010	0.010	0.014	
		<i>N</i>	8	7	8	5	5	5	7	5	6	
	Study partner	<i>Mean</i>	0.064	0.067	0.064	0.067	0.068	0.069	0.065	0.066	0.062	0.84 (0.63,0.97)
		<i>SD</i>	0.005	0.007	0.006	0.006	0.004	0.004	0.007	0.006	0.006	
		<i>N</i>	5	6	6	5	5	5	6	5	5	
GFAP	Total sample	<i>Mean</i>	147.62	140.967	148.273	130.534	143.213	140.273	142.536	123.011	136.349	0.9 (0.83,0.95)
			4									
		<i>SD</i>	77.600	68.563	89.029	71.707	75.650	70.634	68.234	63.581	69.134	
		<i>N</i>	20	20	21	17	17	17	20	17	17	
	Cognitively Intact	<i>Mean</i>	98.161	105.159	97.122	95.467	109.904	111.400	117.094	97.228	115.692	0.73 (0.49,0.93)
		<i>SD</i>	25.105	26.680	35.601	27.099	37.948	47.691	47.438	35.906	49.709	
		<i>N</i>	7	7	7	7	7	7	7	7	6	
	PLWA	<i>Mean</i>	196.74	185.026	204.898	180.384	195.483	197.520	182.919	166.679	177.503	0.86 (0.7,0.96)
			5									
		<i>SD</i>	90.111	80.013	99.056	75.704	93.266	74.099	76.113	71.305	75.510	
		<i>N</i>	8	7	8	5	5	5	7	5	6	
	Study partner	<i>Mean</i>	138.27	131.342	132.451	129.779	137.577	123.448	125.105	115.437	111.753	0.94 (0.85,0.99)
			9									
		<i>SD</i>	65.049	68.577	85.748	92.065	81.464	71.730	66.979	74.387	70.464	
		<i>N</i>	5	6	6	5	5	5	6	5	5	
NfL	Total sample	<i>Mean</i>	23.415	21.750	22.150	22.279	23.550	23.821	22.445	21.413	21.031	0,97 (0.94,0.98)
		<i>SD</i>	11.023	10.870	12.087	11.539	11.638	10.991	11.922	11.171	11.601	
		<i>N</i>	20	20	21	17	17	17	20	17	17	
	Cognitively Intact	<i>Mean</i>	17.935	17.141	16.552	17.117	17.804	18.529	17.490	17.069	17.752	0.93 (0.83,0.98)
		<i>SD</i>	7.012	5.757	7.056	6.707	5.677	6.123	6.638	5.751	7.422	
		<i>N</i>	7	7	7	7	7	7	7	7	6	

PLWA	<i>Mean</i>	26.948	25.942	27.439	25.279	28.854	29.074	27.455	23.782	24.570	0.87 (0.73,0.97)
	<i>SD</i>	6.569	5.243	7.881	3.200	6.131	4.028	7.119	5.320	4.383	
	<i>N</i>	8	7	8	5	5	5	7	5	6	
Study partner	<i>Mean</i>	25.433	22.237	21.629	26.508	26.291	25.976	22.379	25.125	20.719	0.99 (0.97,1)
	<i>SD</i>	18.582	17.933	18.676	19.356	18.801	17.930	18.892	19.079	20.258	
	<i>N</i>	5	6	6	5	5	5	6	5	5	

Table 2. Plasma biomarker levels (pg/mL, mean \pm SD): evening vs morning.

Variable	Group	Time point	Mean	SD	ICC (95% CI)
P-tau217 (N = 21)	Total sample	<i>p.m.</i>	0.767	0.676	0.93 (0.83,0.97)
		<i>a.m.</i>	0.653	0.519	
	Cognitively intact	<i>p.m.</i>	0.348	0.129	0.94 (0.72,0.99)
		<i>a.m.</i>	0.332	0.114	
	PLWA	<i>p.m.</i>	1.323	0.810	0.86 (0.5,0.97)
		<i>a.m.</i>	1.144	0.591	
Study partner	<i>p.m.</i>	0.515	0.269	0.95 (0.74,0.99)	
	<i>a.m.</i>	0.455	0.243		
A β 40 (N = 38)	Total sample	<i>p.m.</i>	126.617	27.178	0.76 (0.58,0.86)
		<i>a.m.</i>	120.833	22.196	
	Cognitively intact	<i>p.m.</i>	127.628	26.383	0.67 (0.38,0.84)
		<i>a.m.</i>	121.050	22.276	
	PLWA	<i>p.m.</i>	134.932	31.770	0.84 (0.44,0.97)
		<i>a.m.</i>	129.656	20.061	
Study partner	<i>p.m.</i>	111.484	21.460	0.97 (0.82,1)	
	<i>a.m.</i>	109.710	22.910		
A β 42 (N = 38)	Total sample	<i>p.m.</i>	7.898	1.907	0.88 (0.78,0.93)
		<i>a.m.</i>	7.722	1.667	
	Cognitively intact	<i>p.m.</i>	7.914	2.106	0.87 (0.73,0.94)
		<i>a.m.</i>	7.750	1.771	
	PLWA	<i>p.m.</i>	8.475	1.643	0.89 (0.58,0.98)
		<i>a.m.</i>	8.162	1.527	
Study partner	<i>p.m.</i>	7.062	1.171	0.88 (0.44,0.98)	
	<i>a.m.</i>	7.104	1.458		
A β 42/A β 40 (N = 38)	Total sample	<i>p.m.</i>	0.063	0.011	0.91 (0.83,0.95)
		<i>a.m.</i>	0.064	0.010	
	Cognitively intact	<i>p.m.</i>	0.062	0.012	0.91 (0.8,0.96)
		<i>a.m.</i>	0.064	0.011	
	PLWA	<i>p.m.</i>	0.064	0.013	0.95 (0.78,0.99)
		<i>a.m.</i>	0.063	0.010	
Study partner	<i>p.m.</i>	0.064	0.006	0.82 (0.25,0.97)	
	<i>a.m.</i>	0.065	0.007		
GFAP (N = 38)	Total sample	<i>p.m.</i>	148.756	77.933	0.83 (0.7,0.91)
		<i>a.m.</i>	145.723	65.281	
	Cognitively intact	<i>p.m.</i>	134.118	61.617	0.87 (0.72,0.94)
		<i>a.m.</i>	139.782	59.893	
	PLWA	<i>p.m.</i>	204.898	99.056	0.69 (0.09,0.93)
		<i>a.m.</i>	182.919	76.113	
Study partner	<i>p.m.</i>	132.451	85.748	0.95 (0.75,0.99)	
	<i>a.m.</i>	125.105	66.979		
NFL (N = 38)	Total sample	<i>p.m.</i>	22.500	9.626	0.93 (0.87,0.96)
		<i>a.m.</i>	23.344	9.679	

Cognitively intact	<i>p.m.</i>	21.072	6.597	0.84 (0.66,0.93)
	<i>a.m.</i>	22.345	6.887	
PLWA	<i>p.m.</i>	27.439	7.881	0.87 (0.52,0.97)
	<i>a.m.</i>	27.455	7.119	
Study partner	<i>p.m.</i>	21.629	18.676	0.99 (0.97,1)
	<i>a.m.</i>	22.379	18.892	

Two PROC MIXED models using two datasets were run as well as an extended model as described in the Data Analysis section. The model using the nine timepoint comparison showed that there was a significant main effect of time for all biomarkers ($p < 0.01$) except GFAP ($p = 0.065$) (Table 3). Figure 1 shows plasma biomarker levels (LS-means) for all participants across 24-hours. For plasma p-tau217 (LS-means) lowest values were observed in the morning, shortly after wake time, after which levels rose to highest values in the afternoon and evening. Thus, p-tau217 concentrations in the first two samples after wake time were significantly lower ($p < 0.0001$) compared to the evening (3 hours before habitual bedtime) sample. For A β 40 and A β 42, higher levels were observed in the afternoon/evening hours with peak levels during the sleep episode and lowest levels in the morning hours. NfL levels peaked overnight with similar levels in the evening and morning hours. The magnitude of the diurnal variation (change in LS-means expressed as a percentage from the overall mean) was: 14.0% (A β 40), 15.3% (A β 42), 4.6% (A β 42/ A β 40), 10.6% (NfL), 17.0% (GFAP), 15.8% (p-tau217).

A significant effect of group was observed for p-tau217 ($p = 0.003$) (Figure 2) with highest levels observed in PLWA, and the effect of group approached significance for GFAP ($p = 0.069$). For none of the biomarkers a significant group by time interaction was observed. For p-tau217, the magnitude of the diurnal variation in PLWA estimated from the LS-means (0.233 ± 0.044 , LS-mean \pm SE) was 27% of the difference between the mean values

for cognitively intact adults (0.349 ± 0.164 , LS-mean \pm SE) and PLWA (1.215 ± 0.153 , LS-mean \pm SE).




Figure 1. Levels of plasma biomarkers (LS-means +/- SE) across a 24-hour period: p-tau217, A β 40, A β 42, A β 42/A β 40, NfL, GFAP. The grey shading indicates the habitual sleep episode. Φ indicates an overall significant effect of time. Asterisk symbol indicates a significant difference in levels between the indicated timepoints; *** = $p < 0.0001$, ** = $p < 0.01$, * = $p < 0.05$.

Table 3. Summary of PROC MIXED analysis for plasma biomarkers over nine timepoints.

Variable	Main effect (N = 21)					
	Time		Group		Time*Group	
	F (DF)	p	F (DF)	p	F (DF)	p
P-tau217	4.29 (8,121)	0.0001	8.57 (2,17.9)	0.003	1.28 (16,121)	0.219
A β 40	4.78 (8,121)	<.0001	0.72 (2,17.9)	0.501	0.92 (16,121)	0.549
A β 42	6.36 (8,121)	<.0001	0.98 (2,17.9)	0.393	0.66 (16,121)	0.824
A β 42/A β 40	3 (8,121)	0.0042	1.46 (2,18)	0.259	1 (16,121)	0.466
GFAP	1.91 (8,121)	0.065	3.1 (2,18)	0.069	1.26 (16,121)	0.232
NfL	2.05 (8,121)	0.046	1.41 (2,18)	0.270	0.91 (16,121)	0.558

To further establish the effects of time we compared evening to morning samples. In this comparison data were available for 38 participants for all biomarkers except p-tau217 (n = 21). PROC MIXED analysis on the two timepoints only (Table 4) revealed significant effects of time, group, and group by time interaction for p-tau217 only.

Table 4. Summary of PROC MIXED analysis for plasma biomarkers over two timepoints.

Variable	N	Main effect					
		Time		Group		Time*Group	
		F (DF)	p	F (DF)	P	F (DF)	p
P-tau217	21	7.77 (1,17)	0.013	7.35 (2,17.9)	0.005	3.66 (2,17)	0.048
A β 40	38	3.86 (1,32.6)	0.058	1.19 (2,34.2)	0.315	0.42 (2,32.6)	0.662
A β 42	38	1.89 (1,32.9)	0.179	0.73 (2,34.7)	0.488	0.54 (1,32.9)	0.5869
A β 42/A β 40	38	1.38 (1,33.1)	0.248	0.09 (2,35)	0.914	0.18 (2,331.1)	0.839
GFAP	38	2.9 (1,33)	0.098	1.9 (2,34.8)	0.165	2.87 (2,33)	0.071
NfL	38	0.27 (1,33.2)	0.606	1.03 (2,35.1)	0.367	0.72 (2,33.2)	0.495




Figure 2. Levels of plasma p-tau217 (LS-means +/- SE) across a 24-hour period in PLWA, their Study Partners, and Cognitively Intact older adults. Blue symbols represent cognitively intact older adults, green symbols represent Study Partners, and orange symbols represent PLWA. The grey shading indicates the habitual sleep episode. *** indicates a significant ($p < 0.0001$) difference in levels between the indicated timepoints in PLWA. The data for the Study Partners and the Cognitively Intact older adults are displaced by 15 minutes so that the variance indicators of the various groups are visible.

When the extended PROC MIXED model was run for the nine timepoint dataset, the effects of time remained significant for p-tau217, A β 40, A β 42, A β 42/ A β 40, and NfL. For p-tau217 the effect of group remained significant and a significant interaction between time and group emerged. A significant effect of age was observed for GFAP ($p = 0.036$). No

significant effects of sex, BMI, PSQI or AHI were observed for any of the biomarkers (Supplementary Table 1). For the two timepoint dataset (Supplementary Table 2), a similar significant effect of age was observed for GFAP ($p = 0.006$) and for p-tau217 the significant effects of time, group, and group*time remained.

Discussion

Here, we show that levels of commonly used plasma biomarkers in dementia research including p-tau217, A β 40, A β 42, A β 42/A β 40, and NfL vary with time-of-day. This significant variation with time-of-day was observed despite the rather large ICC values (range 0.76 – 0.97), which indicate that the between participant variation is greater than within participant variation. The ICCs reported here are in line with previous studies which investigated the longitudinal reliability of plasma biomarkers and observed ICC values between 0.66 and 0.78 [14]. Our observed impact of age on GFAP levels is in line with previous observations in people living with Parkinson's disease where GFAP was shown to correlate with both age and MMSE [15].

We observed significant time-of-day variation for p-tau217, NfL, A β 40, A β 42, and A β 42/A β 40 with the effect approaching significance for GFAP, with the magnitude of diurnal variation ranging from 4.6 – 15.8% for the significant effects. Previous work has demonstrated that cerebrospinal (CSF) levels of amyloid-beta fluctuate with time of day [16-18]. The observed diurnal fluctuations for A β 40 and A β 42 were 2.6% and 0.4%, respectively, for amyloid-positive participants, with the highest values in the early afternoon and lowest values upon waking [17]. This compares to a 14.0% for A β 40 and 15.3% for A β 42 diurnal variation in plasma observed in the current study.

The shape of the diurnal variation varied across the biomarkers. For p-tau217 highest values were observed before bedtime and lowest values upon awakening. For A β 40, and A β 42, we observed highest values during the nocturnal sleep period and lowest values upon waking. A previous study of A β 40, and A β 42 in CSF showed levels were lower in the morning with highest values were in the afternoon [17]. For NfL, highest values were also observed during the sleep period with lowest values in mid-morning and relatively stable levels in the afternoon/evening and morning. Larger sample sizes are needed to further determine the precise shape of this diurnal variation and differences therein across the biomarkers.

The factors underlying the observed diurnal variation remain to be identified. They could be related to circadian modulation of production, phosphorylation, clearance from the brain or could be a response to behavioural changes/processes across the 24-hour day including sleep, meals, or posture. In the latter case, simple behavioural constraints could remove the variance and samples could be taken at any time, whereas in the former case, sample should be taken within particular time windows or values should be corrected for time of day. The observed differences in the shape and timing of the diurnal variation across the biomarkers make it unlikely that one common mechanism, such as changes in blood volume, or circadian or sleep mediated clearance from the brain into the circulation drives all of this diurnal variation.

Although the time-of-day effects we observed may appear small, when they are placed in the context of disease or treatment monitoring, they become of clinical interest. For example, plasma p-tau217 has recently become a biomarker of interest in AD research due to its sensitivity for discriminating for AD, its ability to predict cognitive decline, and its capacity to track response to DMT [8, 9, 19]. Of particular interest is a study in cohorts of A β

positive individuals (n = 171) who were cognitively unimpaired [8]. In this study cognition was assessed using the mini-mental state examination (MMSE) and the modified preclinical Alzheimer Cognitive Composite (mPACC) over a median of six years. Plasma p-tau217 was shown to be the strongest biomarker for predicting cognitive decline and also conversion to AD [8]. Of particular relevance to our findings is that longitudinal monitoring in those with A β -positive prodromal AD showed an increase in p-tau217 of 14.7% per year [20]. This is very similar to the magnitude of the diurnal variation (15.8%) observed in the current study. This change is also meaningful when we consider that in the TRAILBLAZER-ALZ clinical trial following treatment with donanemab for up to 72 weeks, plasma-tau217 levels declined by 23% [9] and GFAP levels decreased by 12%, whereas under placebo both biomarkers increased by 6 and 15%. These percentages are also within the range of the systematic effect of time of day observed in our study.

Of the plasma biomarkers assessed in the TRAILBLAZER Trial (GFAP, NfL, p-tau217, and A β 42/A β 40) only p-tau217 was positively and significantly associated with baseline amyloid plaques and global tau deposition. It is of interest that in our small sample only p-tau217 showed a significant group effect.

For now, our results suggest that time of day matters when considering sampling for plasma biomarkers of dementia for monitoring disease progression or treatment outcome. Samples obtained at an early morning clinic may provide different results to those taken in an afternoon or evening clinic. Time of day should be standardised or at least recorded when samples are collected whether for diagnosis or monitoring their clinical status longitudinally. Recent studies suggest that biomarker concentrations also vary by food intake [21]. For now, we recommend that reference limits for biomarkers related to

neurodegenerative dementias are established in samples collected fasting and in the morning, and that samples for dementia diagnostics are collected accordingly.

Acknowledgements

This work is supported by the UK Dementia Research Institute, Care Research and Technology Centre at Imperial College, London and the University of Surrey, Guildford, United Kingdom which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, as well as the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003), Alzheimer's Society and Alzheimer's Research UK. We thank Surrey Clinical Research Facility for support with recruitment and residential sessions, in particular Kat Pizzoferro for her oversight of sample collection and processing.

Conflict of Interest

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Celectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare that they have no conflicts of interest related to this research.

References

1. Blennow K, Galasko D, Perneczky R, Quevenco FC, van der Flier WM, Akinwonmi A *et al*. The potential clinical value of plasma biomarkers in Alzheimer's disease. *Alzheimers Dement* 2023.
2. 2020 Alzheimer's disease facts and figures. *Alzheimers Dement* 2020.
3. Bittner T. Editorial: What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer's Disease Can Be Used in Clinical Practice? *J Prev Alzheimers Dis* 2022; **9**(4): 567-568.
4. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S *et al*. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. *J Prev Alzheimers Dis* 2022; **9**(2): 197-210.
5. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M *et al*. Lecanemab in Early Alzheimer's Disease. *N Engl J Med* 2023; **388**(1): 9-21.
6. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J *et al*. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA* 2023; **330**(6): 512-527.
7. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate Use Recommendations. *J Prev Alzheimers Dis* 2021; **8**(4): 398-410.
8. Mattsson-Carlgrén N, Salvado G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H *et al*. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. *JAMA Neurol* 2023; **80**(4): 360-369.
9. Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S *et al*. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA Neurol* 2022; **79**(12): 1250-1259.
10. Durrington HJ, Gioan-Tavernier GO, Maidstone RJ, Krakowiak K, Loudon ASI, Blaikley JF *et al*. Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. *Am J Respir Crit Care Med* 2018; **198**(12): 1578-1581.
11. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. *Int Psychogeriatr* 1997; **9 Suppl 1**: 87-94; discussion 143-150.
12. Ravindran GKK, della Monica C, Atzori G, Lambert D, Hassanin H, Revell V *et al*. Three Contactless Sleep Technologies Compared to Actigraphy and Polysomnography in a Heterogenous Group of Older Men and Women in a Model of Mild Sleep Disturbance: A Sleep Laboratory Study. *JMIR mHealth and uHealth* 2023; **25/08/2023:46338 - (forthcoming/in press)**.

13. Ravindran KKG, della Monica C, Atzori G, Lambert D, Hassanin H, Revell V *et al.* Contactless and Longitudinal Monitoring of Nocturnal Sleep and Daytime Naps in Older Men and Women: A Digital Health Technology Evaluation Study. *Sleep* 2023.
14. Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR *et al.* Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid. *Alzheimers Dement* 2023.
15. Tang Y, Han L, Li S, Hu T, Xu Z, Fan Y *et al.* Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. *NPJ Parkinsons Dis* 2023; **9**(1): 23.
16. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. *Neurology* 2007; **68**(9): 666-669.
17. Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V *et al.* Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. *PLoS One* 2014; **9**(3): e89998.
18. Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ. Diurnal oscillation of CSF Aβ and other AD biomarkers. *Mol Neurodegener* 2017; **12**(1): 36.
19. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E *et al.* Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA* 2020; **324**(8): 772-781.
20. Mattsson-Carlgrén N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O *et al.* Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. *Brain* 2020; **143**(11): 3234-3241.
21. Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS *et al.* Levels of Alzheimer's disease blood biomarkers are altered after food intake-A pilot intervention study in healthy adults. *Alzheimers Dement* 2023.